Yintoni i-FeNO kunye ne-Clinical Utility ye-FeNO

Yintoni iNitric Oxide?

I-nitric oxide yigesi eveliswa ziiseli ezibandakanyeka ekuvuvukeni okunxulunyaniswa ne-allergy okanye i-eosinophilic asthma.

 

Yintoni iFeNO?

Uvavanyo lwe-Fractional exhaled Nitric Oxide (FeNO) yindlela yokulinganisa ubungakanani be-nitric oxide kumoya ophumayo. Olu vavanyo lunokunceda ekuxilongweni kwe-asthma ngokubonisa inqanaba lokuvuvukala emiphungeni.

 

Ukusetyenziswa kwezonyango kwe-FeNO

I-FeNO inokubonelela ngesisombululo esingangenisi ntsholongwane sokuxilongwa kokuqala kwesifo sesifuba, i-ATS kunye ne-NICE ziyincoma njengenxalenye yezikhokelo zabo zangoku kunye neendlela zokuxilonga.

Abantu abadala

Abantwana

I-ATS (2011)

Phezulu: >50 ppb

Phakathi: 25-50 ppb

Iphantsi:<25 ppb

Phezulu: >35 ppb

Phakathi: 20-35 ppb

Iphantsi:<20 ppb

I-GINA (2021)

≥ 20 ppb

I-Nice (2017)

≥ 40 ppb

>35 ppb

Isivumelwano saseScotland (2019)

>40 ppb ICS-naive izigulane

>Izigulane ezingama-25 ze-ppb ezithatha i-ICS

Izifinyezo: I-ATS, i-American Thoracic Society; i-FeNO, i-fractional exhaled nitric oxide; i-GINA, i-Global Initiative ye-Asthma; i-ICS, i-corticosteroid ephefumliweyo; i-NICE, iZiko leSizwe lezeMpilo kunye nokuGqwesa koKhathalelo.

Izikhokelo ze-ATS zichaza amanqanaba aphezulu, aphakathi, kunye naphantsi e-FeNO kubantu abadala njenge >50 ppb, 25 ukuya ku-50 ppb, kunye ne <25 ppb, ngokwahlukeneyo. Ngelixa ebantwaneni, amanqanaba aphezulu, aphakathi, kunye naphantsi e-FeNO achazwa njenge >35 ppb, 20 ukuya ku-35 ppb, kunye ne <20 ppb (Itheyibhile 1). I-ATS icebisa ukusetyenziswa kwe-FeNO ukuxhasa ukuxilongwa kwe-asthma apho kufuneka ubungqina obuchanekileyo, ngakumbi ekuxilongweni kokuvuvukala kwe-eosinophilic. I-ATS ichaza ukuba amanqanaba aphezulu e-FeNO (>50 ppb kubantu abadala kunye ne >35 ppb kubantwana), xa itolikwa kwimeko yeklinikhi, ibonisa ukuba ukuvuvukala kwe-eosinophilic kukho kunye nokuphendula kwe-corticosteroid kwizigulana ezineempawu, ngelixa amanqanaba aphantsi (<25 ppb kubantu abadala kunye <20 ppb kubantwana) enza ukuba la manqanaba angenakwenzeka kwaye aphakathi afanele atolikwe ngononophelo.

Izikhokelo zangoku ze-NICE, ezisebenzisa amanqanaba aphantsi e-FeNO cut-off kune-ATS (Itheyibhile 1), zicebisa ukusetyenziswa kwe-FeNO njengenxalenye yomsebenzi wokuxilongwa apho kuqwalaselwa khona ukuxilongwa kwe-asthma kubantu abadala okanye apho kukho ukungaqiniseki kokuxilongwa ebantwaneni. Amanqanaba e-FeNO aphinda atolikwe kwimeko yeklinikhi kwaye uvavanyo olongezelelweyo, olufana novavanyo lwe-bronchial provocation lunokunceda ukuxilongwa ngokubonisa ukusabela okugqithisileyo kwendlela yomoya. Izikhokelo ze-GINA ziyayivuma indima ye-FeNO ekuchongeni ukudumba kwe-eosinophilic kwi-asthma kodwa okwangoku aziboni indima ye-FeNO kwi-algorithms yokuxilonga i-asthma. I-Scottish Consensus ichaza ukususwa ngokwe-steroid exposure kunye namaxabiso amahle e->40 ppb kwizigulane ezingena-steroid kunye ne->25 ppb kwizigulane ezikwi-ICS.

 


Ixesha lokuthumela: Matshi-31-2022